24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
APRELIEVA 150MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | APRELIEVA 150MG |
|---|---|
| Composition | Fosaprepitant Dimeglumine for Injection 150mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
Fosaprepitant Dimeglumine for Injection 150mg (Fosaprepitant Dimeglumine for Injection 150mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
APRELIEVA 150 mg contains Fosaprepitant Dimeglumine, a neurokinin-1 (NK1) receptor antagonist. It is a prodrug of aprepitant and works by blocking substance P in the brain, thereby preventing chemotherapy-induced nausea and vomiting (CINV), especially delayed emesis.
Fosaprepitant is used for prevention of:
1. Chemotherapy-Induced Nausea and Vomiting (CINV)
– Associated with highly emetogenic chemotherapy (HEC)
– Associated with moderately emetogenic chemotherapy (MEC)
It is used in combination with:
• A 5-HT3 receptor antagonist (e.g., ondansetron)
• Dexamethasone
Common side effects:
• Fatigue
• Hiccups
• Headache
• Constipation or diarrhea
Injection-site reactions:
• Pain
• Erythema
• Phlebitis
Serious side effects (rare):
• Hypersensitivity reactions
• Anaphylaxis
Monitor for infusion-site reactions.
Standard adult dose:
• 150 mg IV single dose
• Administered 30 minutes before chemotherapy on Day 1
Replaces 3-day oral aprepitant regimen.
NOTE: This medicine should be taken only under a doctor’s supervision.